Alnylam Pharmaceuticalsvs.Amgen
ALNY vs AMGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 7.4× larger than Alnylam Pharmaceuticals by market cap; Amgen trades at the lower P/E (25.8 vs 37.6); year to date, Amgen leads (+35.6% vs −40.6%).
Side by side
| ALNY | AMGN | |
|---|---|---|
| Market cap | $30.4B | $226B |
| Price | $240.08 | $442.24 |
| Today | +1.7% | −0.4% |
| Return YTD | −40.6% | +35.6% |
| Return 1Y | −48.1% | +51.1% |
| P/E | 37.6 | 25.8 |
| P/S | 6.3 | 5.9 |
| P/B | 22.4 | 19.3 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →More ALNY & AMGN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and AMGN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →